Form 4: Dermata CEO Boosts Stake via Private Placement

Dermata Therapeutics CEO Gerald T. Proehl acquired common stock and warrants in a private placement and amended an existing warrant, increasing his beneficial ownership.

Summary

• Gerald T. Proehl, Dermata Therapeutics' President, Chairman, CEO, Director, and 10% Owner, reported transactions involving common stock and warrants.
• Proehl participated in a private placement on December 23, 2025, purchasing common stock along with Series C and Series D warrants at a price of $2.04 per share and accompanying warrants.
• The Proehl Family Trust acquired 490,196 shares of common stock, 490,196 Series C Warrants, and 490,196 Series D Warrants.
• The Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 acquired 122,549 shares of common stock, 122,549 Series C Warrants, and 122,549 Series D Warrants.
• An outstanding warrant issued on January 3, 2025, with an exercise price of $12.70, was amended to an exercise price of $2.04. This was reported as a cancellation of the old warrant and purchase of a replacement warrant for 78,740 shares.
• The transactions are exempt from Section 16(b) under Rule 16b-3(d)(1) for the private placement and Rule 16b-3(e) for the warrant amendment.
• A one-for-10 reverse stock split was effected by the Issuer on August 1, 2025, which is reflected in the reported amounts.
• Warrants will become exercisable upon stockholder approval of the issuance of shares, with Series C warrants expiring five years and Series D warrants expiring two years from the approval date.
• Warrant exercise is subject to a 9.99% beneficial ownership limitation for the reporting person and affiliates.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant insider buying by the CEO, Chairman, and 10% owner, indicating strong confidence in the company's future. The amendment of an existing warrant to a lower exercise price also suggests a move to make it more attractive for exercise, potentially bringing more capital. However, the contingency of warrant exercisability on stockholder approval introduces a slight element of uncertainty.

Positives

• Increased beneficial ownership by the CEO, Chairman, and 10% owner, Gerald T. Proehl, signals strong insider confidence in Dermata Therapeutics' future.
• The private placement provides capital to the company, strengthening its financial position.
• The amendment of an existing warrant to a lower exercise price ($12.70 to $2.04) makes it more likely to be in-the-money and exercised, potentially bringing additional capital to the company.

Negatives

• The issuance of new shares and warrants in the private placement could lead to dilution for existing shareholders.
• The exercisability of the Series C and Series D warrants is contingent on stockholder approval, introducing a potential hurdle.
• The 9.99% beneficial ownership limitation on warrant exercise could restrict the reporting person's ability to fully exercise their warrants if not managed carefully.

Risks

• Stockholder approval risk: The issuance of shares upon exercise of the Series C and Series D warrants requires stockholder approval, which is not guaranteed.
• Dilution risk: Future exercise of the warrants will increase the number of outstanding shares, potentially diluting the value of existing shares.
• Market price risk: The value of the warrants and the underlying common stock is subject to market fluctuations, which could impact the profitability of the investment for the reporting person.
• Regulatory compliance risk: While the transactions are reported as exempt from Section 16(b), ongoing compliance with SEC regulations is required.

Future Outlook

The future outlook is tied to the company's ability to secure stockholder approval for the issuance of shares underlying the Series C and Series D warrants. If approved, these warrants could be exercised, potentially bringing additional capital to the company over the next two to five years, depending on the warrant series.

Management Comments

• The filing reports that Gerald T. Proehl, in his capacity as CEO, Chairman, and Director, engaged in a private placement to acquire common stock and warrants, demonstrating a direct investment in the company's equity.
• Management also amended an existing warrant, adjusting its exercise price to align with the private placement terms, indicating a strategic move to optimize existing equity instruments.

Industry Context

This filing primarily details an insider transaction, which is a company-specific event rather than a reflection of broader industry trends. However, insider buying, especially by a CEO, can be interpreted by the market as a positive signal regarding the company's prospects within its industry, suggesting management believes the stock is undervalued or has significant upside potential.

Related Party Transactions

• Gerald T. Proehl, the reporting person, is the President, Chairman, CEO, Director, and 10% Owner of Dermata Therapeutics, Inc.
• The transactions involve purchases by the Proehl Family Trust and the Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020, which are entities related to Gerald T. Proehl.
• Other indirect holdings are through the Allison Taylor Proehl 2020 Irrevocable Trust, Meghan Proehl Wilder 2020 Irrevocable Trust, and Proehl Investment Ventures LLC, all related to the reporting person.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrants, but also a strong signal of confidence from the CEO, which could positively influence investor sentiment.
• Company: Receives capital from the private placement, strengthening its financial position. Potential for additional capital upon warrant exercise.
• Management: Gerald T. Proehl increases his direct and indirect beneficial ownership, aligning his interests more closely with long-term shareholder value.

Next Steps

• Obtain stockholder approval for the issuance of shares of common stock issuable upon exercise of the Series C and Series D warrants.
• The Series C warrants will become exercisable upon stockholder approval and expire five years thereafter.
• The Series D warrants will become exercisable upon stockholder approval and expire two years thereafter.

Key Dates

Recommendation

The significant insider buying by the CEO, Chairman, and 10% owner, Gerald T. Proehl, is a strong positive signal, indicating management's confidence in the company's prospects. This type of transaction often precedes positive developments. However, as a Form 4 primarily reports ownership changes and not comprehensive financial results or strategic updates, a 'hold' recommendation is prudent. Investors should consider this insider activity as a positive indicator but also conduct further due diligence on the company's financials, pipeline, and overall market conditions before making a 'buy' decision. The contingency of warrant exercise on stockholder approval also adds a layer of uncertainty.

Keywords

Dermata Therapeutics, DRMA, Gerald T. Proehl, Insider Trading, Private Placement, Warrants, Common Stock, Beneficial Ownership, SEC Form 4, Reverse Stock Split